Dengue virus vaccine composition

• Main Authors: Castro Velazco Jorge, Pérez Fuentes Yusleidi de la Caridad, Pérez Guevara Olga Lidia, Hermida Cruz Lisset, Garcia Arechavaleta Angelica de la Caridad, Ramírez Bartutis Rosa Liset, Suzarte Portal Edith, Lazo Vazquez Laura, Marcos López Ernesto, Guzmán Tirado María Guadalupe, López Fernández Lázaro, Alvarez Vera Mayling, Romero Fernández Yaremy, Izquierdo Oliva Alienys, Guillén Nieto Gerardo Enrique, Valdés Prado Iris, Gil González Lázaro
• Format: Patent
• Language: English
• Published: 11.10.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.